SG11201901642XA - Constitutively active cytokine receptors for cell therapy - Google Patents

Constitutively active cytokine receptors for cell therapy

Info

Publication number
SG11201901642XA
SG11201901642XA SG11201901642XA SG11201901642XA SG11201901642XA SG 11201901642X A SG11201901642X A SG 11201901642XA SG 11201901642X A SG11201901642X A SG 11201901642XA SG 11201901642X A SG11201901642X A SG 11201901642XA SG 11201901642X A SG11201901642X A SG 11201901642XA
Authority
SG
Singapore
Prior art keywords
international
houston
constitutively active
street
active cytokine
Prior art date
Application number
SG11201901642XA
Inventor
Thomas C T Shum
Stephen M G Gottschalk
Bilal Omer
Cliona M Rooney
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of SG11201901642XA publication Critical patent/SG11201901642XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0 iivi HIM 3E1 0 01111 OM 1111110E111 EMI ill OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/038945 Al 01 March 2018 (01.03.2018) W I P0 I P C T (51) International Patent Classification: C07K 14/00 (2006.01) A61K 38/19 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/046588 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) — 11 August 2017 (11.08.2017) with sequence listing part of description (Rule 5.2(a)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/380,021 26 August 2016 (26.08.2016) US (71) Applicant: BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza, Houston, TX 77030 (US). (72) Inventors: SHUM, Thomas C.T.; 1885 El Paseo Street, Apt. 411, Houston, TX 77054 (US). GOTTSCHALK, Stephen M.G.; 1908 Canterbury, Houston, TX 77030 (US). OMER, Bilal; 1300 Bomar Street, Houston, TX 77006 _ (US). ROONEY, Cliona M.; 4802 Willow Street, Bellaire, TX 77401 (US). — = Agent: SISTRUNK, Melissa L. et al.; Norton Rose Ful- (74) bright US LLP, 1301 McKinney, Suite 5100, Houston, TX = 77010-3095 (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (81) = = = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = — 1-1 kin ii- tz. M en (54) Title: CONSTITUTIVELY ACTIVE CYTOKINE RECEPTORS FOR CELL THERAPY ---- (57) : Embodiments of the disclosure include methods and compositions for enhancing expansion of immune cells for im- GC , 1 munotherapy. In particular embodiments, immune cells, such as T-cells, express a constitutively active cytokine receptor in which the C::::) transmembrane and endodomains are able to provide an activating signal separately from any input to the corresponding exodomain N to which they are operably linked. In specific embodiments, the transmembrane and endodomain from IL-7Ra is utilized with the e m \") exodomain of CD34.
SG11201901642XA 2016-08-26 2017-08-11 Constitutively active cytokine receptors for cell therapy SG11201901642XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380021P 2016-08-26 2016-08-26
PCT/US2017/046588 WO2018038945A1 (en) 2016-08-26 2017-08-11 Constitutively active cytokine receptors for cell therapy

Publications (1)

Publication Number Publication Date
SG11201901642XA true SG11201901642XA (en) 2019-03-28

Family

ID=61245226

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901642XA SG11201901642XA (en) 2016-08-26 2017-08-11 Constitutively active cytokine receptors for cell therapy

Country Status (9)

Country Link
US (1) US20190183936A1 (en)
EP (1) EP3504223A4 (en)
JP (2) JP7107579B2 (en)
KR (2) KR20230167769A (en)
CN (2) CN109952309A (en)
AU (1) AU2017317022B2 (en)
CA (1) CA3034873A1 (en)
SG (1) SG11201901642XA (en)
WO (1) WO2018038945A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP3759132A1 (en) 2018-03-02 2021-01-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
KR20210025525A (en) * 2018-06-22 2021-03-09 카이트 파마 인코포레이티드 Chimeric transmembrane protein and uses thereof
US20210379107A1 (en) * 2018-06-25 2021-12-09 Peter Maccallum Cancer Institute Modified t cells and uses thereof
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
TW202039537A (en) * 2018-11-27 2020-11-01 美商昂科賽克醫療公司 Plasmid constructs for treating cancer and methods of use
CN113891718A (en) * 2019-02-21 2022-01-04 艾贝乐医药科技有限公司 Artificial immune surveillance chimeric antigen receptor (AI-CAR) and cells expressing same
BR112021017365A2 (en) * 2019-03-01 2022-02-01 Allogene Therapeutics Inc constitutively active chimeric cytokine receptors
KR20210136042A (en) 2019-03-01 2021-11-16 알로젠 테라퓨틱스 인코포레이티드 Chimeric Cytokine Receptors Carrying the PD-1 Ectodomain
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
US20210061881A1 (en) * 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
CN110564695A (en) * 2019-09-23 2019-12-13 华东师范大学 Enhanced CAR-T cell targeting prostate cancer and preparation method and medicine thereof
AU2020379848A1 (en) * 2019-11-06 2022-05-19 Baylor College Of Medicine Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
IL295470A (en) * 2020-02-24 2022-10-01 Allogene Therapeutics Inc Bcma car-t cells with enhanced activities
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
CN111518219B (en) * 2020-05-08 2021-06-22 浙江大学 Chimeric antigen receptor, macrophage expressing same, method for regulating macrophage polarization and application
CN115698038A (en) * 2020-06-01 2023-02-03 上海君赛生物科技有限公司 Signal transduction receptors and uses thereof
CN112190692B (en) * 2020-09-30 2023-03-31 复旦大学附属妇产科医院 Use of NrCAM in the manufacture of a medicament
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN115066433A (en) 2021-02-10 2022-09-16 苏州克睿基因生物科技有限公司 Amplification enhancer and application thereof
EP4319799A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CN117441010A (en) 2021-04-07 2024-01-23 世纪治疗股份有限公司 Compositions and methods for producing alpha-beta T cells from induced pluripotent stem cells
CA3218235A1 (en) 2021-04-27 2022-11-03 Baylor College Of Medicine Virus-specific immune cells expressing chimeric antigen receptors
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
JPWO2023276395A1 (en) * 2021-06-28 2023-01-05
KR20230022810A (en) * 2021-08-06 2023-02-16 한국생명공학연구원 Novel Anti-EphA2 Chimeric Antigen Receptor and Immune Cell Expressing the Same
WO2024059629A1 (en) * 2022-09-13 2024-03-21 Imunon, Inc. Il-12 gene therapy and immune checkpoint inhibitor combination for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2010085643A1 (en) * 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
WO2011066344A1 (en) * 2009-11-25 2011-06-03 Dana-Farber Cancer Institute, Inc. Crlf2 in precursor b-cell acute lymphoblastic leukemia
ES2649967T3 (en) * 2011-04-08 2018-01-16 Baylor College Of Medicine Reversal of the effects of the tumor microenvironment using cytokine chimeric receptors
ES2888651T3 (en) * 2011-07-29 2022-01-05 Univ Pennsylvania costimulatory switching receptors
ES2774160T3 (en) * 2012-02-13 2020-07-17 Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP3470423B1 (en) 2013-04-17 2021-10-06 Baylor College of Medicine Immunosuppressive tgf-beta signal converter
MA41538A (en) 2014-10-17 2017-12-26 Baylor College Medicine BIPARTITE AND TRIPARTITE IMMUNE CELLS OF SIGNALING
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
KR20210025525A (en) * 2018-06-22 2021-03-09 카이트 파마 인코포레이티드 Chimeric transmembrane protein and uses thereof

Also Published As

Publication number Publication date
JP2019528078A (en) 2019-10-10
KR20190039597A (en) 2019-04-12
JP2022119868A (en) 2022-08-17
AU2017317022B2 (en) 2021-12-09
AU2017317022A1 (en) 2019-03-14
EP3504223A1 (en) 2019-07-03
WO2018038945A1 (en) 2018-03-01
US20190183936A1 (en) 2019-06-20
CN109952309A (en) 2019-06-28
JP7107579B2 (en) 2022-07-27
CA3034873A1 (en) 2018-03-01
EP3504223A4 (en) 2020-03-25
KR102608966B1 (en) 2023-12-04
CN116970630A (en) 2023-10-31
KR20230167769A (en) 2023-12-11

Similar Documents

Publication Publication Date Title
SG11201901642XA (en) Constitutively active cytokine receptors for cell therapy
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201909949XA (en) Targeted immunotolerance
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201909749PA (en) Oncolytic virotherapy and immunotherapy
SG11201908796XA (en) Improved antigen binding receptors
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201408261UA (en) Syringe
SG11201407898WA (en) Electrode testing apparatus
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201907319QA (en) Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
SG11201408051VA (en) Cho expression system
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908980PA (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof